X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AJANTA PHARMA with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AJANTA PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
ADCOCK INGRAM
Jun-14
AJANTA PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,720353-   
Low Rs1,103255-   
Sales per share (Unadj.) Rs194.6105.0-  
Earnings per share (Unadj.) Rs45.2-26.5-  
Cash flow per share (Unadj.) Rs50.3-21.9-  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.082.4-  
Shares outstanding (eoy) m88.77168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.32.9 250.7%   
Avg P/E ratio x31.2-11.5 -271.8%  
P/CF ratio (eoy) x28.1-13.9 -202.5%  
Price / Book Value ratio x10.73.7 290.0%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,29951,290 244.3%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m2,5703,219 79.8%   
Avg. sales/employee Rs ThNM4,129.2-  
Avg. wages/employee Rs ThNM749.8-  
Avg. net profit/employee Rs ThNM-1,040.5-  
INCOME DATA
Net Sales Rs m17,27517,727 97.5%  
Other income Rs m166124 134.0%   
Total revenues Rs m17,44217,851 97.7%   
Gross profit Rs m5,807-3,072 -189.0%  
Depreciation Rs m451765 58.9%   
Interest Rs m49480 10.2%   
Profit before tax Rs m5,474-4,193 -130.5%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460262 557.2%   
Profit after tax Rs m4,014-4,467 -89.9%  
Gross profit margin %33.6-17.3 -194.0%  
Effective tax rate %26.7-6.2 -426.8%   
Net profit margin %23.2-25.2 -92.2%  
BALANCE SHEET DATA
Current assets Rs m7,63912,983 58.8%   
Current liabilities Rs m2,7157,305 37.2%   
Net working cap to sales %28.532.0 89.0%  
Current ratio x2.81.8 158.3%  
Inventory Days Days43111 39.0%  
Debtors Days Days79124 63.5%  
Net fixed assets Rs m6,9147,568 91.4%   
Share capital Rs m17782 214.9%   
"Free" reserves Rs m11,4420-   
Net worth Rs m11,72113,914 84.2%   
Long term debt Rs m1494,889 3.0%   
Total assets Rs m14,81426,284 56.4%  
Interest coverage x112.9-7.7 -1,460.7%   
Debt to equity ratio x00.4 3.6%  
Sales to assets ratio x1.20.7 172.9%   
Return on assets %27.4-15.2 -180.8%  
Return on equity %34.2-32.1 -106.7%  
Return on capital %46.5-19.8 -234.9%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Net fx Rs m8,7440-   
CASH FLOW
From Operations Rs m3,2641,513 215.7%  
From Investments Rs m-2,093-465 450.5%  
From Financial Activity Rs m-1,1864,438 -26.7%  
Net Cashflow Rs m-155,486 -0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.87 Rs / ZAR

Compare AJANTA PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare AJANTA PHARMA With: WOCKHARDT LTD.  DR. REDDYS LAB  PIRAMAL ENTERPRISES  SUVEN LIFE  ALEMBIC LTD  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - PLETHICO PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS